The excitement around psilocybin research for the treatment of depressive disorders has spurred momentum worldwide.

Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety ...

A small pilot study from the Center for Psychedelic Research at Imperial College London indicates that psilocybin—the active ...

Compass Pathways Plc shares fell almost 10% Tuesday after a pivotal study of its experimental psilocybin-based therapy ...

New evidence for psilocybin benefits found in study © 2026 American City Business Journals. All rights reserved. Use of ...

Psilocybin—the active ingredient in "magic" mushrooms—is a more effective treatment for symptoms of depression than controls, providing further support for its potential as an antidepressant, suggests ...

Oregon’s landmark effort allowing adults older than 21 to access psilocybin has evolved beyond “strictly medical uses” and ...

Oregon regulators want to double licensing fees for psilocybin businesses. Owners say the proposed increases could slow ...

A 43-year-old San Diego County man pleaded guilty last week to trafficking psilocybin mushrooms and using his two young sons ...

I think it clearly lends itself to somebody who is not used to taking these types of medications being left alone and ...

A 43-year-old California man pleaded guilty last week to trafficking psilocybin mushrooms and using his two young sons in the ...